Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4609855 | 0.91 | MAPK14 (0.59) | MAPK14KCNH3 | |
| SCHEMBL4609467 | 0.90 | MAPK14 (0.73) | MAPK14 | |
| SCHEMBL4608984 | 0.89 | MAPK14 (0.72) | MAPK14 | |
| SCHEMBL4609031 | 0.87 | MAPK14 (0.56) | MAPK14 | |
| SCHEMBL4608756 | 0.87 | MAPK14 (0.74) | MAPK14 | |
| SCHEMBL4625334 | 0.87 | MAPK14 (0.74) | MAPK14 | |
| SCHEMBL4608358 | 0.86 | MAPK14 (0.58) | MAPK14KCNH3 | |
| SCHEMBL4610044 | 0.85 | MAPK14 (0.55) | MAPK14 | |
| SCHEMBL4609265 | 0.85 | MAPK14 (0.55) | MAPK14 | |
| SCHEMBL5009411 | 0.84 | MAPK14 (0.53) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449474-B2 | Tri-substituted ureas as cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2008-11-11 | — | — | US | disclosed |
| EP-1747204-B1 | TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS | PROCTER & GAMBLE (US) | 2008-07-30 | — | — | EP | disclosed |
| CN-1946701-A | Trisubstituted ureas as cytokine inhibitors | PROCTER & GAMBLE (US) | 2007-04-11 | — | — | CN | disclosed |
| US-20050239811-A1 | Tri-substituted ureas as cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239811-A1 | Tri-substituted ureas as cytokine inhibitors | IL1B, IL1A, IL6 | MAPK14 2674/4885KCNH3 4835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.